Yousef, Abdelrahman http://orcid.org/0000-0001-7761-8149
Yousef, Mahmoud http://orcid.org/0009-0007-2550-4837
Chowdhury, Saikat http://orcid.org/0000-0002-0783-3959
Abdilleh, Kawther
Knafl, Mark http://orcid.org/0000-0002-3953-2173
Edelkamp, Paul http://orcid.org/0000-0001-5881-8292
Alfaro-Munoz, Kristin
Chacko, Ray
Peterson, Jennifer
Smaglo, Brandon G. http://orcid.org/0000-0002-8814-8004
Wolff, Robert A.
Pant, Shubham
Lee, Michael S.
Willis, Jason http://orcid.org/0000-0001-8238-8552
Overman, Michael
Doss, Sudheer
Matrisian, Lynn http://orcid.org/0000-0002-5631-2826
Hurd, Mark W.
Snyder, Rebecca
Katz, Matthew H. G.
Wang, Huamin
Maitra, Anirban
Shen, John Paul http://orcid.org/0000-0003-4588-2775
Zhao, Dan http://orcid.org/0000-0001-7066-9058
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RR180035)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA016672)
Article History
Received: 22 July 2023
Accepted: 5 January 2024
First Online: 3 February 2024
Competing interests
: D.Z. has clinical trial contracts with Mirati and CARsgen and served as a member of the advisory board for Affini-T.K.A., S.D., and L.M. are employees of the Pancreatic Cancer Action Network, a nonprofit cancer advocacy organization that receives donations from private and commercial entities and may benefit indirectly financially and non-financially from this publication. S.P. reports research funding from Mirati Therapeutics, Lilly, Xencor, Novartis, Rgenix, Bristol-Myers Squibb, Astellas Pharma, Framewave, 4D Pharma, Boehringer Ingelheim, NGM Biopharmaceuticals, Janssen, Arcus Biosciences, Elicio Therapeutics, Bionote, Ipsen, Zymeworks, Pfizer, ImmunoMET, Immuneering, Amal Therapeutics. S.P. is a member of the advisory board for Zymeworks, Ipsen, Novartis, Janssen, Boehringer Ingelheim, AskGene Pharma, BPGbio, Jazz Pharmaceuticals, AstraZeneca, US WorldMeds, Nihon Medi-Physics Co., Ltd., Alligator Bioscience. M.L. consults for Pfizer, Delcath, Janssen, BioNTech, G1 Therapeutics, Imvax, and Bayer and received research funding from institutions from EpimAb BioTherapeutics, Merck, Erasca, Boehringer Ingelheim, Arcus Biosciences, Repare Therapeutics, Trisalus Life Sciences, and Xilis. A.M. is a consultant for Tezcat Biotechnologies and is a co-inventor on a patent that has been licensed from Johns Hopkins University by Thrive Earlier Detection (an Exact Sciences company). A.M. serves on the scientific and medical advisory board for Pancreatic Cancer Action Network and Pancreatic Cancer UK. J.P.S. receives grants, research support, or collaborates with Celsius Therapeutics, BostonGene, Caris Life Sciences, Natera, Xilis, Palantir, and Genentech. J.P.S. reports consulting and stock ownership with Engine Biosciences, NaDeNo Nanoscience.